Page last updated: 2024-10-28

1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Diabetic Retinopathy

1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Diabetic Retinopathy in 6 studies

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.

Diabetic Retinopathy: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.

Research Excerpts

ExcerptRelevanceReference
"This study evaluates the effect of intravitreal injection of a Rho-associated protein kinase (ROCK) inhibitor, fasudil, on diabetic macular edema (DME) with an unfavorable response."8.12Intravitreal Fasudil for Treatment of Diabetic Macular Edema with an Unfavorable Response. ( Machida, S; Muto, T, 2022)
"This study evaluates the effect of intravitreal injection of a Rho-associated protein kinase (ROCK) inhibitor, fasudil, on diabetic macular edema (DME) with an unfavorable response."4.12Intravitreal Fasudil for Treatment of Diabetic Macular Edema with an Unfavorable Response. ( Machida, S; Muto, T, 2022)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Muto, T1
Machida, S1
Rothschild, PR1
Salah, S1
Berdugo, M1
Gélizé, E1
Delaunay, K1
Naud, MC1
Klein, C1
Moulin, A1
Savoldelli, M1
Bergin, C1
Jeanny, JC1
Jonet, L1
Arsenijevic, Y1
Behar-Cohen, F1
Crisanti, P1
Ahmadieh, H2
Nourinia, R2
Hafezi-Moghadam, A2
Sabbaghi, H1
Nakao, S1
Zandi, S1
Yaseri, M1
Tofighi, Z1
Akbarian, S1
Kita, T1
Arita, R1

Reviews

2 reviews available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Diabetic Retinopathy

ArticleYear
[Molecular mechanisms of preretinal membrane contraction in proliferative vitreoretinal diseases and ROCK as a therapeutic target].
    Nippon Ganka Gakkai zasshi, 2010, Volume: 114, Issue:11

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetic Retinopathy; Molecular Targeted The

2010
[Mechanism of diabetes-induced microvascular damage and therapeutic potential of ROCK inhibition].
    Nippon Ganka Gakkai zasshi, 2011, Volume: 115, Issue:11

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetic Angiopathies; Diabetic Retinopathy;

2011

Trials

1 trial available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Diabetic Retinopathy

ArticleYear
Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.
    The British journal of ophthalmology, 2019, Volume: 103, Issue:7

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Di

2019

Other Studies

3 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Diabetic Retinopathy

ArticleYear
Intravitreal Fasudil for Treatment of Diabetic Macular Edema with an Unfavorable Response.
    Seminars in ophthalmology, 2022, Feb-17, Volume: 37, Issue:2

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Diabetes Mellitus; Diabetic Retinopathy; Humans

2022
ROCK-1 mediates diabetes-induced retinal pigment epithelial and endothelial cell blebbing: Contribution to diabetic retinopathy.
    Scientific reports, 2017, 08-18, Volume: 7, Issue:1

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Animals; Biomarkers; Case-Control Studies; Cyto

2017
Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema: a novel treatment.
    JAMA ophthalmology, 2013, Volume: 131, Issue:7

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal

2013